Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Pharvaris Offering Announcement: Pharvaris N.V. has priced an underwritten offering of 8,250,000 ordinary shares at $20.00 each and pre-funded warrants for 500,000 shares at $19.99, aiming to raise approximately $175 million before expenses, with the offering expected to close around July 24, 2025.
Company Overview: Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases like hereditary angioedema, currently conducting pivotal Phase 3 studies for its product, deucrictibant.
Trade with 70% Backtested Accuracy
Analyst Views on PHVS
About PHVS
About the author
Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73
Price Target Update: The average one-year price target for Pharvaris N.V. has been revised to $45.73 per share, reflecting a 20.90% increase from the previous estimate of $37.82, with a range from $30.30 to $80.85 per share.
Fund Sentiment: There has been a 29.21% increase in the number of funds reporting positions in Pharvaris, with total shares owned by institutions rising by 28.49% to 58,210K shares, and an average portfolio weight of 1.67%.
Shareholder Activity: General Atlantic increased its holdings in Pharvaris by 6.23% to 8,031K shares, while Foresite Capital Management Iv and venBio Partners also reported increases in their share ownership, with venBio Partners slightly decreasing its portfolio allocation.
Market Outlook: The put/call ratio for Pharvaris is at 0.93, indicating a bullish sentiment among investors, suggesting positive expectations for the stock's performance.
Stocks Rise on Hope for Fed Rate Cuts
Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed higher on Wednesday, with the S&P 500 and Nasdaq reaching three-week highs, supported by a weaker-than-expected ADP employment report that lowered bond yields and increased expectations for a Fed interest rate cut.
Sector Highlights: Chipmakers saw significant gains, with Microchip Technology rising over 12% after a strong earnings forecast, while other tech stocks also performed well. Conversely, concerns over AI demand affected Microsoft, which saw a decline in stock price.
Economic Indicators: The November ADP employment report indicated an unexpected job loss of 32,000, the largest drop in over 2.5 years, while the ISM services index showed unexpected growth, suggesting mixed signals in the labor market and economic activity.
Upcoming Economic Focus: Market attention is on upcoming economic reports, including unemployment claims and personal spending, with a high probability of a 25 basis point rate cut anticipated at the next FOMC meeting on December 9-10.
Stocks Bounce Back Amid Anticipation of Fed Rate Cuts
Market Performance: The S&P 500 is up 0.18%, while the Dow Jones is up 0.47%, and the Nasdaq 100 is down 0.06%. Stock indexes recovered from early losses due to falling bond yields and expectations of a Fed interest rate cut following a weaker-than-expected ADP employment report.
Labor Market Concerns: The November ADP employment report revealed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market's strength and its implications for economic growth.
Corporate Earnings and Economic Indicators: Q3 earnings for S&P 500 companies have exceeded forecasts, with a 14.6% increase, while the ISM services index unexpectedly rose, indicating stronger service-sector activity. Market attention is on upcoming economic reports, including unemployment claims and personal spending.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology saw significant gains, while stocks like Pure Storage and Gitlab faced declines due to disappointing forecasts. Additionally, cryptocurrency-related stocks rose as Bitcoin reached a two-week high.
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.
Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.
Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.
Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.
Stocks Weaken Amid Labor Market Struggles and AI Demand Worries
Market Performance: The S&P 500 is down 0.15%, while the Dow Jones is up 0.05% and the Nasdaq 100 is down 0.49%. Stock futures are mixed due to concerns over a weaker US labor market and reduced AI demand from Microsoft.
Economic Indicators: The November ADP employment report showed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market and increasing expectations for a Fed interest rate cut.
Corporate Earnings: Q3 earnings season is concluding with 83% of S&P 500 companies exceeding forecasts, resulting in a 14.6% rise in earnings, significantly above the expected 7.2% increase.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology are seeing gains, while Microsoft and Pure Storage are among the notable losers due to disappointing forecasts and reports.
Pharvaris' Deucrictibant Significantly Reduces HAE Symptom Relief Time
- Significant Efficacy: Deucrictibant achieved a median time to symptom relief of 1.28 hours in clinical trials, significantly faster than the placebo's over 12 hours (p<0.0001), indicating its potential value in acute HAE attacks.
- Comprehensive Endpoint Achievement: All 11 secondary efficacy endpoints reached statistical significance, with a median time to complete symptom resolution of 11.95 hours compared to over 24 hours for placebo, showcasing Deucrictibant's rapid action mechanism.
- Good Safety Profile: Deucrictibant showed no treatment-related serious adverse events during the trial, with 93.2% of patients requiring only a single dose for treatment within 12 hours, indicating its excellent tolerability in clinical use.
- Broad Market Potential: Pharvaris plans to submit a New Drug Application (NDA) to the FDA in the first half of 2026, which, if approved, will provide the first oral on-demand treatment option for HAE patients, addressing the urgent market need for effective and convenient therapies.
Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73
Price Target Update: The average one-year price target for Pharvaris N.V. has been revised to $45.73 per share, reflecting a 20.90% increase from the previous estimate of $37.82, with a range from $30.30 to $80.85 per share.
Fund Sentiment: There has been a 29.21% increase in the number of funds reporting positions in Pharvaris, with total shares owned by institutions rising by 28.49% to 58,210K shares, and an average portfolio weight of 1.67%.
Shareholder Activity: General Atlantic increased its holdings in Pharvaris by 6.23% to 8,031K shares, while Foresite Capital Management Iv and venBio Partners also reported increases in their share ownership, with venBio Partners slightly decreasing its portfolio allocation.
Market Outlook: The put/call ratio for Pharvaris is at 0.93, indicating a bullish sentiment among investors, suggesting positive expectations for the stock's performance.
Stocks Rise on Hope for Fed Rate Cuts
Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed higher on Wednesday, with the S&P 500 and Nasdaq reaching three-week highs, supported by a weaker-than-expected ADP employment report that lowered bond yields and increased expectations for a Fed interest rate cut.
Sector Highlights: Chipmakers saw significant gains, with Microchip Technology rising over 12% after a strong earnings forecast, while other tech stocks also performed well. Conversely, concerns over AI demand affected Microsoft, which saw a decline in stock price.
Economic Indicators: The November ADP employment report indicated an unexpected job loss of 32,000, the largest drop in over 2.5 years, while the ISM services index showed unexpected growth, suggesting mixed signals in the labor market and economic activity.
Upcoming Economic Focus: Market attention is on upcoming economic reports, including unemployment claims and personal spending, with a high probability of a 25 basis point rate cut anticipated at the next FOMC meeting on December 9-10.
Stocks Bounce Back Amid Anticipation of Fed Rate Cuts
Market Performance: The S&P 500 is up 0.18%, while the Dow Jones is up 0.47%, and the Nasdaq 100 is down 0.06%. Stock indexes recovered from early losses due to falling bond yields and expectations of a Fed interest rate cut following a weaker-than-expected ADP employment report.
Labor Market Concerns: The November ADP employment report revealed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market's strength and its implications for economic growth.
Corporate Earnings and Economic Indicators: Q3 earnings for S&P 500 companies have exceeded forecasts, with a 14.6% increase, while the ISM services index unexpectedly rose, indicating stronger service-sector activity. Market attention is on upcoming economic reports, including unemployment claims and personal spending.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology saw significant gains, while stocks like Pure Storage and Gitlab faced declines due to disappointing forecasts. Additionally, cryptocurrency-related stocks rose as Bitcoin reached a two-week high.
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.
Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.
Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.
Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.
Stocks Weaken Amid Labor Market Struggles and AI Demand Worries
Market Performance: The S&P 500 is down 0.15%, while the Dow Jones is up 0.05% and the Nasdaq 100 is down 0.49%. Stock futures are mixed due to concerns over a weaker US labor market and reduced AI demand from Microsoft.
Economic Indicators: The November ADP employment report showed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market and increasing expectations for a Fed interest rate cut.
Corporate Earnings: Q3 earnings season is concluding with 83% of S&P 500 companies exceeding forecasts, resulting in a 14.6% rise in earnings, significantly above the expected 7.2% increase.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology are seeing gains, while Microsoft and Pure Storage are among the notable losers due to disappointing forecasts and reports.
Pharvaris' Deucrictibant Significantly Reduces HAE Symptom Relief Time
- Significant Efficacy: Deucrictibant achieved a median time to symptom relief of 1.28 hours in clinical trials, significantly faster than the placebo's over 12 hours (p<0.0001), indicating its potential value in acute HAE attacks.
- Comprehensive Endpoint Achievement: All 11 secondary efficacy endpoints reached statistical significance, with a median time to complete symptom resolution of 11.95 hours compared to over 24 hours for placebo, showcasing Deucrictibant's rapid action mechanism.
- Good Safety Profile: Deucrictibant showed no treatment-related serious adverse events during the trial, with 93.2% of patients requiring only a single dose for treatment within 12 hours, indicating its excellent tolerability in clinical use.
- Broad Market Potential: Pharvaris plans to submit a New Drug Application (NDA) to the FDA in the first half of 2026, which, if approved, will provide the first oral on-demand treatment option for HAE patients, addressing the urgent market need for effective and convenient therapies.
